Jun 1, 2020 by Brian Orelli, PhDModerna Starts a Phase 2 Clinical Trial for Its COVID-19 VaccineThe vaccine is advancing through clinical trials at lightning speed.
May 29, 2020 by Brian Orelli, PhDMerck's Keytruda Better Than Chemotherapy for Certain Colon CancersThe blockbuster cancer treatment delivered strong results in another clinical trial.
May 28, 2020 by Brian Orelli, PhDFDA Says COVID-19 Could Delay Drug ApprovalsThe pandemic is pulling the agency in different directions.
May 28, 2020 by Brian Orelli, PhDGlaxoSmithKline Plans to Produce 1 Billion Doses of Its Pandemic Vaccine Adjuvant in 2021Simply put, adjuvants make vaccines work better; this one could be useful in conjunction with a number of SARS-CoV-2 vaccine candidates.
May 26, 2020 by Brian Orelli, PhDSanofi to Sell Its 20.6% Stake in Regeneron, but Keep Their Collaboration IntactThe sale appears to be more about Sanofi's capital needs than about Regeneron's valuation.
May 22, 2020 by Brian Orelli, PhDIntercept Pharmaceuticals Shares Fall 13% After FDA Delays an Advisory Committee MeetingInvestors are feeling more uncertainty about whether obeticholic acid will be approved as a treatment for liver fibrosis due to nonalcoholic steatohepatitis.
May 21, 2020 by Brian Orelli, PhDGlaxoSmithKline Teams Up With Mammoth Biosciences on a CRISPR-Based COVID-19 TestThe test could diagnose individuals in 20 minutes without the need for lab equipment.
May 20, 2020 by Brian Orelli, PhDJohnson & Johnson Plans to Stop Selling Talc-Based Baby PowderSales have dropped due to cancer concerns.
May 19, 2020 by Brian Orelli, PhDHere's Why Sorrento Therapeutics Dropped 16.6% TodayWhat goes up, must come down.
May 19, 2020 by Brian Orelli, PhDGlaxoSmithKline, Pfizer, and Shionogi's HIV Prevention Candidate Outperforms Gilead's TruvadaA study showed that cabotegravir works better than the current pre-exposure prophylaxis treatment, but there may be issues with getting it approved.
May 18, 2020 by Brian Orelli, PhDModerna Plans to Raise $1.25 Billion in a Secondary OfferingShares of the COVID-19 vaccine drugmaker are up 339% this year.
May 16, 2020 by Brian Orelli, PhDClovis Oncology Secures FDA Approval for Rubraca in Prostate CancerRubraca is the first PARP inhibitor approved for prostate cancer.
May 15, 2020 by Brian Orelli, PhDPfizer Posts Positive Data from Duchenne Muscular Dystrophy Candidate, but Still Trails Rival Sarepta TherapeuticsThe big pharma is jumping straight to a phase 3 clinical trial for the gene therapy PF-06939926.
May 14, 2020 by Brian Orelli, PhDLegend Biotech Makes Plans to IPO With Backing From Johnson & JohnsonThe startup aims to take on bluebird bio and Bristol Myers Squibb with its CAR-T therapy targeting BCMA for multiple myeloma.
May 12, 2020 by Brian Orelli, PhDHere's Why Shares of Durect Jumped Higher TodayThe biotech becomes a COVID-19 play and benefits from a competitor's failure.
May 11, 2020 by Brian Orelli, PhDHere's Why Shares of BioCryst Pharmaceuticals Jumped Higher TodayInvestors are still hot on the idea that its antiviral drug galidesivir could be used for COVID-19.
May 8, 2020 by Brian Orelli, PhDHere's Why Evolent Health Shares Jumped TodayThis healthcare company appears to be pretty healthy.
May 7, 2020 by Brian Orelli, PhDHere's Why Teva Pharmaceuticals Jumped Higher TodayThe drugmaker had a nice turnaround quarter, but will it last?
May 5, 2020 by Brian Orelli, PhDGilead Sciences Plans to Expand Global Supply of RemdesivirThe ebola-turned-coronavirus treatment will be needed globally.
